In the present study, we tested the hypothesis that chronic treatment with the direct rennin inhibitor aliskiren improves the remodelling of resistance arteries in dTGR (double-transgenic rats). dTGR (5 weeks) were treated with aliskiren (3 mg/kg of body mass per day) or ramipril (1 mg/kg of body mass per day) for 14 days and compared with age-matched vehicle-treated dTGR. BP (blood pressure) was similarly reduced in both aliskiren-treated and ramipril-treated rats compared with control dTGR (167±1 and 169±2 mmHg compared with 197±4 mmHg respectively; P<0.05). The M/L (media-to-lumen) ratio assessed on pressurized preparations was equally reduced in aliskiren-treated and ramipril-treated rats compared with controls (6.3±0.5 and 6.4±0.2% compared with 9.8±0.4% respectively; P<0.05). Endothelium-dependent and -independent relaxations were similar among the groups. L-NAME (N(G)-nitro-L-arginine methyl ester) significantly reduced acetylcholine-induced dilation in drug-treated dTGR. This effect was significantly more prominent in aliskiren-treated rats. eNOS (endothelial NO synthase) expression showed a 2-fold increase only in aliskiren-treated dTGR as compared with controls (P<0.01) and ramipril-treated dTGR (P<0.05). Plasma nitrite, as an index of NO production, was significantly increased in dTGR treated with either aliskiren or ramipril compared with controls. Only aliskiren induced a 2-fold increase in plasma nitrite, which was significantly greater than that induced by ramipril (P<0.05). gp91(phox) expression and ROS (reactive oxygen species) production in aorta were significantly and similarly reduced by both drugs. In conclusion, equieffective hypotensive doses of aliskiren or ramipril reduced the M/L ratio of mesenteric arteries and improved oxidative stress in dTGR. However, only aliskiren increased further NO production in the vasculature. Hence, in dTGR, direct renin inhibition induces favourable effects similar to that induced by ACE (angiotensin-converting enzyme) inhibition in improving vascular remodelling through different mechanisms.

Download full-text PDF

Source
http://dx.doi.org/10.1042/CS20120395DOI Listing

Publication Analysis

Top Keywords

inhibitor aliskiren
8
aliskiren improves
8
mg/kg body
8
body mass
8
mass day
8
direct renin
4
renin inhibitor
4
improves vascular
4
vascular remodelling
4
remodelling transgenic
4

Similar Publications

Background: Cognitive impairment is common in patients with heart failure and preserved ejection fraction but its clinical correlates and prognostic associations are poorly understood.

Methods: We analyzed cognitive function, using the Mini-Mental State Examination (MMSE), in patients with heart failure and preserved ejection fraction enrolled in a prespecified substudy of the PARAGON-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in Heart Failure With Preserved Ejection Fraction). Logistic regression analyses were performed to determine the variables associated with lower MMSE scores at baseline and postbaseline decline in MMSE scores at 48 weeks.

View Article and Find Full Text PDF

Marked activation of the renin-angiotensin-aldosterone system (RAAS) plays an important role in malignant hypertension (MHT) by worsening hypertension and renal function. The rates of readmission for severe hypertension and cardiovascular disease in such emergencies are high, suggesting that suppression of the RAAS may be inadequate during the acute phase in some cases. This report presents a case of MHT complicated with renal insufficiency (creatinine 3.

View Article and Find Full Text PDF
Article Synopsis
  • Sacubitril/valsartan is a medication that helps reduce the risk of cardiovascular death and hospital stays due to heart failure in people with chronic heart failure (HF), especially among older patients with other health issues.* -
  • The study analyzed data from two major trials (PARADIGM-HF and PARAGON-HF) to determine the impact of sacubitril/valsartan on all-cause hospitalizations in patients with different levels of heart function (measured as left ventricular ejection fraction - LVEF).* -
  • Results showed that sacubitril/valsartan lowered the risk of all-cause hospitalization compared to standard heart medications, with a median follow-up of about 2.5
View Article and Find Full Text PDF
Article Synopsis
  • Researchers studied serum levels of 4123 proteins in 1117 patients with heart failure with preserved ejection fraction (HFpEF) to identify prognostic markers linked to clinical outcomes.
  • A total of 288 proteins were found to be significantly associated with heart failure hospitalization and cardiovascular death, with specific proteins like B2M and TIMP1 showing strong correlations.
  • The study concluded that the protein markers for HFpEF are similar to those for heart failure with reduced ejection fraction, implying that the derived proteomic risk scores do not offer improved predictive power for HFpEF patients.
View Article and Find Full Text PDF
Article Synopsis
  • - The study investigated whether the heart failure medication sacubitril/valsartan could lead to cognitive impairment, as it affects enzymes that degrade amyloid-β peptides, which are linked to Alzheimer's disease.
  • - Researchers used the Mini-Mental State Examination (MMSE) to assess cognitive function changes over 96 weeks in a subset of heart failure patients from the PARAGON-HF trial, comparing those on sacubitril/valsartan to those on valsartan alone.
  • - Results showed no significant difference in cognitive decline between the two groups, with both medications resulting in nearly identical changes in MMSE scores, suggesting sacubitril/valsartan does not have a negative effect on cognitive function in these patients. *
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!